Adaptive Biotechnologies officer sells 165,802 shares
Adaptive Biotechnologies Corp Chief Commercial Officer for Immune Medicine, Sharon Benzeno, reported a series of option exercises and related stock sales.
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp Chief Commercial Officer for Immune Medicine, Sharon Benzeno, reported a series of option exercises and related stock sales. She exercised options for 114,329 shares of common stock at strike prices between $3.99 and $12.14 per share.
On June 26 and 29, 2026, she sold a total of 165,802 shares in open-market transactions at weighted-average prices of $21.00 and $21.14 per share. After these transactions, she directly holds 221,278 shares of Adaptive Biotechnologies common stock.
The filing notes that all transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
12 txns
Insider
BENZENO SHARON
Role
Chief Commercial Ofc Imm Med
Sold
165,802 shs ($3.50M)
Approx. gross sale proceeds
$3.50M
Approx. exercise cost
$886K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 1,837 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 24,944 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 24,944 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 51,570 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,837 | $12.14 | $22K |
| Exercise | Common Stock | 24,944 | $8.46 | $211K |
| Exercise | Common Stock | 24,944 | $3.99 | $100K |
| Exercise | Common Stock | 51,570 | $8.12 | $419K |
| Sale | Common Stock | 154,768 | $21.14 | $3.27M |
| Exercise | Stock Option (right to buy) | 11,034 | $0.00 | $0.00 |
| Exercise | Common Stock | 11,034 | $12.14 | $134K |
| Sale | Common Stock | 11,034 | $21.00 | $232K |
Holdings After Transaction:
Stock Option (right to buy) — 238,176 contracts (Direct);
Common Stock — 221,278 shares (Direct)
Footnotes (7)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025.
- F2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The option was fully vested and exercisable.
- F5. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F6. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F7. The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Key Figures
Shares sold: 165,802 shares
Options exercised: 114,329 shares
Sale price (June 29): $21.14 per share
+4 more
7 metrics
Shares sold
165,802 shares
Open-market sales on June 26 and 29, 2026
Options exercised
114,329 shares
Total shares acquired via option exercises
Sale price (June 29)
$21.14 per share
Weighted-average price for 154,768-share sale
Sale price (June 26)
$21.00 per share
Weighted-average price for 11,034-share sale
Strike price range
$3.99–$12.14 per share
Exercise prices for options converted to common stock
Shares held after transactions
221,278 shares
Direct common stock ownership after June 29, 2026 trades
Net share change from buys/sells
-165,802 shares
Net of open-market buys and sells (sell-side only here)
Key Terms
Rule 10b5-1 trading plan, weighted-average price, Stock Option (right to buy), Exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported for this transaction is a weighted-average price."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ADPT officer Sharon Benzeno report?
Sharon Benzeno reported exercising stock options for 114,329 Adaptive Biotechnologies shares and selling 165,802 shares in open-market trades. The transactions combined option exercises at lower strike prices with sales around $21 per share, partially reducing but not eliminating her equity stake.
Were the ADPT insider sales made under a Rule 10b5-1 plan?
Yes. The filing states that all reported transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2025. Such plans pre-schedule trades, indicating these sales were arranged in advance rather than timed in response to short-term market developments.
What option strike prices were exercised by the ADPT insider?
The reported option exercises covered strike prices of $3.99, $8.12, $8.46, and $12.14 per share. These exercises converted derivative positions into common stock, which was then partly sold, reflecting a typical exercise-and-sell pattern rather than a simple open-market purchase.
AI-generated analysis. How Rhea-AI works. Not financial advice.
